In view of their near-equal performance, these preliminary studies suggest the routine-use of 18F-PSMA-1007 in lieu of other PSMA-based PET tracers for staging PCa patients, in particular for the reduced urinary clearance and the better target-to-background uptake ratio of 18F-PSMA-1007. This evidence concerns the gene FOLH1 and posterior cortical atrophy.